About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Tag Archives: pharmaceutical pricing
The Growing Profile and Influence of ICER
The year began with a prediction from Senator Mitt Romney to pharmaceutical executives that “change is coming”. There have been high profile hearings on the topic in the Congress and legislation that moved in both the Senate and the House … Continue reading
Posted in Pharma Industry Image, Pricing and Value
Tagged ICER, Pharma, pharmaceutical pricing
Comments Off on The Growing Profile and Influence of ICER
FDA’s Contribution to the Pricing Issue – Generic Activism
As hearings on Capitol Hill these past two months (and in the months to come) have examined the issue of pharmaceutical pricing to inform potential legislation as well as to garner attention, FDA has been addressing the issue in the … Continue reading
Posted in Generic Drugs
Tagged FDA, generics, pharmaceutical pricing
Comments Off on FDA’s Contribution to the Pricing Issue – Generic Activism